Akers Biosciences to Attend Hemp Industry Daily Forum in Las Vegas, Nevada
December 06 2019 - 9:30AM
Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer
of rapid health information technologies, today announced that
Executive Chairman Christopher Schreiber will attend the “Hemp
Industry Daily Forum” on Tuesday, December 10, 2019 as part of
MJBizCon Week at the Las Vegas Convention Center in Las Vegas,
Nevada. Akers Advisory Board member Bob Hoban is a featured speaker
presenting on “International Opportunities” for Hemp operations
within the Textiles to Cannabidiol (CBD) space.
Christopher Schreiber added, “MJBizCon is the
largest gathering of cannabis related business professionals in the
world and a great opportunity for Akers to continue
strategic dialogue with potential partners
and broaden its relationships in the Hemp and
minor cannabinoid space. I look forward to sharing
more information on our growth strategy with investors in
the near future.”
About Akers Biosciences Inc
Akers Biosciences develops, manufactures, and
supplies rapid, point of care screening and testing products
designed to bring health related information directly to the
patient or clinician in a timely and cost-efficient manner.
Forward-Looking Statements
Statements in this press release relating to
plans, strategies, trends, specific activities or investments, and
other statements that are not descriptions of historical facts and
may be forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995, Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. Forward-looking
information is inherently subject to risks and uncertainties, and
actual results could differ materially from those currently
anticipated due to a number of factors, which include the Company’s
expectation regarding the offering and the exercise of the
preferred stock warrants, and the risk that the proposed public
offering will not be consummated, the need for additional
financing, and any risks detailed from time to time in Akers'
reports filed with the Securities and Exchange Commission, Annual
Reports on Form 10-K, Quarterly Reports on Form 10-Q, and Current
Reports on Form 8-K. Forward-looking statements may be identified
by terms such as "may," "will," "expects," "plans," "intends,"
"estimates," "potential," or "continue," or similar terms or the
negative of these terms. Although Akers believes the expectations
reflected in the forward-looking statements are reasonable, they
cannot guarantee that future results, levels of activity,
performance or achievements will be obtained. Akers does not have
any obligation to update these forward-looking statements other
than as required by law.
Additional information on the company and its
products can be found at www.akersbio.com.
Contact:Investor
Relations: Hayden
IR
Brett Mass, Managing
Partner
Phone: (646)
536-7331
Email:
brett@haydenir.com
www.haydenir.com
Akers Biosciences (NASDAQ:AKER)
Historical Stock Chart
From Mar 2024 to Apr 2024
Akers Biosciences (NASDAQ:AKER)
Historical Stock Chart
From Apr 2023 to Apr 2024